{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:37:43Z","timestamp":1785760663468,"version":"3.56.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>SYNGR4 is considered to be one of the causative genes for amyotrophic lateral sclerosis, but its role in breast cancer development has not been revealed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The expression of SYNGR4 in a variety of malignancies including breast cancer was analyzed using Genotype Tissue Expression (GTEx) and the Cancer Genome Atlas (TCGA) databases and verified by specimens collected from our center. The effect of SYNGR4 on breast cancer prognosis was analyzed using bioinformatics and possible pathways by which this molecule affects breast cancer prognosis were explored. The effect of SYNGR4 on immune infiltration of breast cancer was analyzed using GSVA, and the effects of SYNGR4 on breast cancer proliferation, migration, and tumor-associated macrophage polarization in cancer foci were verified by cellular and animal experiments, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>SYNGR4 is highly expressed in a variety of malignant tumors, including breast cancer, and affects the prognosis of breast cancer patients. This may be a volatile effect through Organelle fission, chromosome segregation, nuclear division, etc. SYNGR4 overexpression affects breast cancer proliferation, migration, and tumor immune infiltration, and promotes breast cancer tumor-associated macrophage polarization toward M2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>SYNGR4 overexpression can affect the prognosis of breast cancer patients by promoting M2 polarization of tumor-associated macrophages in breast cancer, and this molecule may be a novel target for breast cancer immunotherapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1490073","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T07:22:08Z","timestamp":1737357728000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Unveiling the role of SYNGR4 in breast cancer development: a novel target for immunotherapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Jie","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwei","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanrong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41416-020-01161-4","article-title":"The lingering mysteries of metastatic recurrence in breast cancer","volume":"124","author":"Riggio","year":"2021","journal-title":"Br J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1471-2164-7-96","article-title":"The molecular portraits of breast tumors are conserved across microarray platforms","volume":"7","author":"Hu","year":"2006","journal-title":"BMC Genomics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5152\/tjbh.2015.1669","article-title":"Molecular classification of breast carcinoma: from traditional, old-fashioned way to A new age, and A new way","volume":"11","author":"Eliyatkin","year":"2015","journal-title":"J Breast Health"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: Prognostic and therapeutic implications","volume":"5","author":"Yersal","year":"2014","journal-title":"World J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2017(04)09","article-title":"Breast cancer screening in developing countries","volume":"72","author":"da Costa Vieira","year":"2017","journal-title":"Clinics (Sao Paulo)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"595167","DOI":"10.1155\/2010\/595167","article-title":"Breast cancer in developing countries: opportunities for improved survival","volume":"2010","author":"Shulman","year":"2010","journal-title":"J Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI57088","article-title":"Insight into the heterogeneity of breast cancer through next-generation sequencing","volume":"121","author":"Russnes","year":"2011","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13058-020-01345-z","article-title":"Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses","volume":"22","author":"Fumagalli","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21145009","article-title":"Immunotherapies and combination strategies for immuno-oncology","volume":"21","author":"Barbari","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"103223","DOI":"10.1016\/j.critrevonc.2021.103223","article-title":"Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials","volume":"159","author":"Tarantino","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0074-7696(02)14004-6","article-title":"Tetraspan vesicle membrane proteins: synthesis, subcellular localization, and functional properties","volume":"214","author":"Hubner","year":"2002","journal-title":"Int Rev Cytol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073646","article-title":"Transcriptional regulation of the synaptic vesicle protein synaptogyrin-3 (SYNGR3) gene: the effects of NURR1 on its expression","volume":"23","author":"Li","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02554","article-title":"Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03)","volume":"40","author":"Gnant","year":"2022","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01027","article-title":"MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2-positive and\/or hormone receptor-negative breast cancers in the I-SPY 2 trial","volume":"38","author":"Chien","year":"2020","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-018-0004-4","article-title":"When worlds collide: Th17 and Treg cells in cancer and autoimmunity","volume":"15","author":"Knochelmann","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1016\/j.celrep.2019.11.113","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"29","author":"Garcia-Diaz","year":"2019","journal-title":"Cell Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01084","article-title":"Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages","volume":"10","author":"Orecchioni","year":"2019","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2012.01.011","article-title":"Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression","volume":"22","author":"Ostrand-Rosenberg","year":"2012","journal-title":"Semin Cancer Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02186-1","article-title":"Preclinical models in head and neck squamous cell carcinoma","volume":"128","author":"Chaves","year":"2023","journal-title":"Br J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12060854","article-title":"Precision medicine in head and neck cancers: genomic and preclinical approaches","volume":"12","author":"Miserocchi","year":"2022","journal-title":"J Pers Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41199-020-00056-4","article-title":"Preclinical models of head and neck\u00a0squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies","volume":"5","author":"Tinhofer","year":"2020","journal-title":"Cancers Head Neck"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1490073\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T07:22:10Z","timestamp":1737357730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1490073\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":29,"alternative-id":["10.3389\/fonc.2024.1490073"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1490073","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"article-number":"1490073"}}